Cancer Unfiltered

Community Health Media

Candid podcast where leading oncologists and experts speak openly about the realities of cancer care. Through honest conversations, real-world insights, and expert perspectives, the show tackles the complex topics shaping oncology today—without the filters.

Episodes

  1. Aug 24

    Cancer Unfiltered Ep. 4: VIKTORIA-1 in HR+ mBC with Drs. Komal Jhaveri & Neil Iyengar

    One trial. One therapy. Countless clinical questions. In Episode 4 of Cancer Unfiltered, Dr. Komal Jhaveri and Dr. Neil Iyengar take a deep dive into the VIKTORIA-1 trial and discuss how gedatolisib may reshape treatment for patients with HR-positive, HER2-negative metastatic breast cancer. Beyond reviewing the data, they explore where this regimen fits in clinical practice, who may benefit most, concerns surrounding toxicity and treatment burden, and how VIKTORIA-1 compares with other rapidly emerging therapies in this evolving treatment landscape. Topics discussed: VIKTORIA-1 trial design and key efficacy results Gedatolisib triplet vs. doublet therapy Managing HR-positive, HER2-negative metastatic breast cancer Intravenous therapy vs. oral treatment options Stomatitis and other treatment-related toxicities Patient selection and co-mutations How PAM pathway inhibition may overcome resistance Sequencing endocrine therapies after progression Emerging trials including FOURLIGHT-1 and selective CDK4 inhibitors The future of targeted therapy in metastatic breast cancer Recorded prior to the July 2026 FDA approval of gedatolisib (Revtorpyk) with fulvestrant, ± palbociclib, for HR-positive, HER2-negative advanced breast cancer without a detectable PIK3CA mutation after progression on prior endocrine therapy. ▶️ Watch on YouTube - https://youtu.be/43BVZ9nL424 🎧 Listen on Spotify, Apple Podcasts, Amazon Music, CastBox & iHeartRadio - https://linkin.bio/cancerunfilteredpodcast/ #CancerUnfiltered #VIKTORIA1 #Gedatolisib #HRPositive #MetastaticBreastCancer #MedicalOncology #BreastCancer #PI3K #PIK3CA #TargetedTherapy #CommunityHealthMedia

    Cancer Unfiltered Ep. 4: VIKTORIA-1 in HR+ mBC with Drs. Komal Jhaveri & Neil Iyengar
  2. Jul 30

    Cancer Unfiltered Ep. 3: New FDA Approvals, Practice-Changing Trials & What's Next in Breast Cancer

    Breast cancer treatment is changing at an unprecedented pace. In Episode 3 of Cancer Unfiltered, Dr. Komal Jhaveri and Dr. Neil Iyengar discuss the latest FDA approvals, landmark clinical trials, and emerging treatment strategies that are reshaping care across HR-positive, HER2-positive, and triple-negative breast cancer. From practice-changing DESTINY data to the expanding role of antibody-drug conjugates, this episode breaks down what the latest evidence means for treatment decisions today. Topics discussed: • Six new FDA approvals across all major breast cancer subtypes • Vepdegestrant and the VERITAC-2 trial for ESR1-mutant HR-positive breast cancer • DESTINY-Breast11, DESTINY-Breast05, and DESTINY-Breast09: key findings and clinical impact • The growing role of antibody-drug conjugates (ADCs) in first-line metastatic triple-negative breast cancer • Treatment sequencing and how new approvals are changing clinical decision-making • Which HER2-positive patients may benefit most from the DESTINY-Breast09 approach • Brain metastases, PIK3CA mutations, and selecting therapy for high-risk patients • Giredestrant and the lidERA trial: improving endocrine therapy options • VIKTORIA-1 and emerging therapies targeting the PI3K/AKT/mTOR (PAM) pathway • The future of breast cancer treatment and practice-changing data to watch Whether you're an oncologist, advanced practice provider, researcher, or healthcare professional, this episode offers practical insights into the rapidly evolving breast cancer treatment landscape and what these developments mean for patient care. ▶️ Watch on YouTube - https://youtu.be/m0l8feuG6Y8 🎧 Listen on Spotify, Apple Podcasts, Amazon Music, CastBox, & iHeartRadio - https://linkin.bio/cancerunfiltered Cancer Unfiltered is part of the Community Health Media Podcast Network, where meaningful conversations help patients, caregivers, advocates, and healthcare professionals learn from one another, one story at a time. #CancerUnfiltered #BreastCancer #Oncology #MedicalOncology #FDAApprovals #DESTINYBreast11 #DESTINYBreast05 #Vepdegestrant #TripleNegativeBreastCancer #HER2Positive #CancerPodcast #CommunityHealthMedia

    Cancer Unfiltered Ep. 3: New FDA Approvals, Practice-Changing Trials & What's Next in Breast Cancer

About

Candid podcast where leading oncologists and experts speak openly about the realities of cancer care. Through honest conversations, real-world insights, and expert perspectives, the show tackles the complex topics shaping oncology today—without the filters.